論文

査読有り 本文へのリンクあり
2020年10月

Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study

World Allergy Organization Journal
  • Kiyotake Ogura
  • ,
  • Noriyuki Yanagida
  • ,
  • Sakura Sato
  • ,
  • Takanori Imai
  • ,
  • Komei Ito
  • ,
  • Naoyuki Kando
  • ,
  • Masanori Ikeda
  • ,
  • Rumiko Shibata
  • ,
  • Yoko Murakami
  • ,
  • Takao Fujisawa
  • ,
  • Mizuho Nagao
  • ,
  • Norio Kawamoto
  • ,
  • Naomi Kondo
  • ,
  • Atsuo Urisu
  • ,
  • Ikuya Tsuge
  • ,
  • Yasuto Kondo
  • ,
  • Kazuko Sugai
  • ,
  • Osamu Uchida
  • ,
  • Mitsuyoshi Urashima
  • ,
  • Masami Taniguchi
  • ,
  • Motohiro Ebisawa

13
10
記述言語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.waojou.2020.100463

© 2020 The Authors Background: Generally, oral immunotherapy (OIT) aims for daily administration. Recently, the efficacy of treatment with OIT at a low dose has been reported. However, the optimal dose and the evaluation of dose-dependent OIT outcome have not been described. Methods: A multicenter, parallel, open-labeled, prospective, non-placebo controlled, randomized study enrolled 101 Japanese patients for treatment with OIT. We hypothesized that target dose OIT would induce short-term unresponsiveness (StU) earlier than reduced dose OIT. StU was defined as no response to 6200 mg whole egg, 3400 mg milk, and 2600 mg wheat protein, as evaluated by oral food challenge after 2-week ingestion cessation. To compare the two doses of OIT efficacy, the maximum ingestion doses during the maintenance phase of OIT were divided into 100%-dose or 25%-dose groups against their target StU dose, respectively. A total of 51 patients were assigned to the 100%-dose group [hen's egg (HE) = 26, cow's milk (CM) = 13, wheat = 12] and 50 to the 25%-dose group (HE = 25, CM = 13, wheat = 12). Primary outcome was established by comparing StU at 1 year. Secondary outcome was StU at 2 years and established by comparing allergic symptoms and immunological changes. Results: The year 1 StU rates (%) for the 100%- and 25%-dose groups were 26.9 vs. 20.0 (HE), 7.7 vs. 15.4 (CM), and 50.0 vs. 16.7 (wheat), respectively. The year 2 StU rates were 30.8 vs. 36.0 (HE), 7.7 vs. 23.1 (CM), and 58.3 vs. 58.3 (wheat), respectively. There were no statistically significant differences in StU between years 1 and 2. The total allergic symptom rate in the 25%-dose group was lower than that in the 100%-dose group for egg, milk, and wheat. Antigen-specific IgE levels for egg-white, milk, and wheat decreased at 12 months. Conclusions: Reduced maintenance dose of egg OIT showed similar therapeutic efficacy to the target dose. However, we were not able to clearly demonstrate the efficacy, particularly for milk and wheat. Reducing the maintenance dose for eggs, milk, and wheat may effectively lower the symptoms associated with their consumption compared to the target OIT dose. Furthermore, aggressive reduction of the maintenance dose might be important for milk and wheat, compared to the 25%-dose OIT. Trial registration: UMIN000009373, Multicenter Oral Immunotherapy for Hen's Egg, Cow's Milk, and Wheat-Allergic Children at Outpatient Clinic.

リンク情報
DOI
https://doi.org/10.1016/j.waojou.2020.100463
Scopus
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85091768768&origin=inward 本文へのリンクあり
Scopus Citedby
https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85091768768&origin=inward

エクスポート
BibTeX RIS